News

Graybug and CalciMedica Enter into Definitive Merger Agreement
November 21, 2022
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases Combined company is expected to …
CalciMedica Announces Publication of Preclinical Data in EMBO Molecular Medicine Supporting the Development of CRAC Channel Inhibitors for Inflammatory Bowel Disease (IBD)
August 9, 2022
– Study provides further validation of the potentially broad utility for CRAC channel inhibitors in inflammatory diseases– Data show that inhibiting store-operated Ca2+ entry (SOCE) …
CalciMedica Initiates CARDEA-Plus: A Clinical Trial of Auxora™ in Patients with Critical COVID-19 Pneumonia
January 20, 2022
CARDEA-Plus is designed to evaluate dosing, safety and efficacy of Auxora in combination with both tocilizumab and corticosteroids LA JOLLA, Calif., January 20, 2022 – CalciMedica …